PRESS RELEASE published on 08/19/2024 at 13:30, 2 years ago MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End MIRA Pharmaceuticals, a leading pre-clinical-stage company, provides an update on its achievements and scientific advancements, nearing a milestone: IND application submission for Ketamir-2 and regulatory progress for MIRA-55 IND Application Scientific Advancements MIRA Pharmaceuticals Regulatory Progress Pre-clinical-stage
PRESS RELEASE published on 08/19/2024 at 13:30, 2 years ago Beyond Oil Announces Publication of Medical Opinion by Professor Sarel Halahmi, Head of Urology Department at Bnei Zion Medical Center-Medical Opinion Concluding that Beyond Oil is Improving Health Safety by Reducing Urological Risks, Bladder Cancer and I Medical opinion highlights health risks of reusing frying oil, citing risks like bladder cancer and infertility. Beyond Oil's filter powder offers a solution. Expert urges global adoption for public health benefits Bladder Cancer Frying Oil Beyond Oil Health Risks Global Solution
PRESS RELEASE published on 08/19/2024 at 13:30, 2 years ago Libsyn Announces Sale of Pair Networks, Leadership Transition Libsyn announces sale of Pair Networks to Your.Online for strategic focus. Leadership succession plan underway. Libsyn leading podcast platform Libsyn Pair Networks Podcasting Your.Online Leadership Succession
PRESS RELEASE published on 08/19/2024 at 13:20, 2 years ago MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials MindBio reports sustained antidepressant response in depressed patients three months post MB22001 treatment. Excellent safety and efficacy shown in Phase 2A clinical trials MindBio Phase 2A Clinical Trials Antidepressant Response MB22001 Treatment Sustained
PRESS RELEASE published on 08/19/2024 at 13:00, 2 years ago Ivanhoe Electric and Ma'aden Joint Venture Commences Drilling Activities in Saudi Arabia Ivanhoe Electric Inc. and Ma'aden Joint Venture to commence drilling in Saudi Arabia following Typhoon™ anomaly detection in Al Amar Belt. Exploration activities expanding into Bir Umq, Wadi Bidah and platform license applications Saudi Arabia Exploration Ma'aden Ivanhoe Electric Inc. Typhoon™
PRESS RELEASE published on 08/19/2024 at 13:00, 2 years ago The Penco Module Advances to the Next Stage of Its Permitting Process Aclara Resources Inc. announces progress in the evaluation process of Penco Module's Environmental Impact Assessment, with reduced observations received and commitment to sustainable rare earth extraction practices Environmental Impact Assessment Sustainability Rare Earth Extraction Aclara Resources Inc. Penco Module
PRESS RELEASE published on 08/19/2024 at 13:00, 2 years ago Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05 Tanvex BioPharma USA, Inc. receives FDA approval for NYPOZI™ biosimilar and FDA BLA acceptance for TX-05, showcasing expertise in biologics development and manufacturing FDA Approval Biologics Tanvex BioPharma NYPOZI TX-05
PRESS RELEASE published on 08/19/2024 at 12:45, 2 years ago Northern Dynasty: Alaska Court Grants Motion to Add USACE to Existing EPA Complaint Northern Dynasty Minerals and Pebble Limited Partnership report U.S. Federal District Court allows addition of US Army Corps of Engineers as defendant in EPA complaint modification Northern Dynasty Minerals Pebble Limited Partnership US Army Corps Of Engineers EPA Complaint Modification US Federal District Court
PRESS RELEASE published on 08/19/2024 at 12:35, 2 years ago Epique Realty Announces Strategic Expansion Into New Mexico and Utah Epique Realty expands into New Mexico and Utah, introducing innovative agent-centric model led by William Lambert. Transformation of real estate industry focus on agent success and inclusivity Expansion Real Estate Industry Epique Realty William Lambert Agent-centric Model
PRESS RELEASE published on 08/19/2024 at 12:30, 2 years ago NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected NanoViricides NV-387 Clinical Trial Antiviral Phase II
Published on 09/15/2026 at 14:31, 13 minutes ago First Breach Secures Federal Explosives License for Attritible Drone Manufacturing
Published on 09/15/2026 at 14:30, 14 minutes ago Predictiv AI Completes End-to-End Logistics Platform for Prompt Xpress's National Delivery Network
Published on 09/15/2026 at 14:00, 44 minutes ago EQ Works and Pattison Media Announce Strategic Partnership to Power Next-Generation Radio Audience Intelligence
Published on 09/15/2026 at 14:00, 44 minutes ago Adcore Named Finalist for Microsoft Advertising Search Performance Partner of the Year 2026
Published on 09/15/2026 at 14:10, 34 minutes ago Carbon credits move into the Boardroom as Nine in Ten Buyers Report Real Business Gains
Published on 09/15/2026 at 14:05, 39 minutes ago Kibar Americas Celebrates Grand Opening of Fairmont Aluminum Manufacturing Facility
Published on 09/15/2026 at 14:05, 39 minutes ago DeepL Voice now preserves your voice in real-time multilingual conversations
Published on 09/15/2026 at 14:05, 39 minutes ago Sopra Steria and Dynatrace launch a dedicated observability and AIOps practice for Europe
Published on 09/15/2026 at 13:33, 1 hour 11 minutes ago WashTec confirms medium- and long-term profitability ambitions
Published on 09/15/2026 at 07:00, 7 hours 44 minutes ago AXA announces its 2027-2029 strategy and financial targets
Published on 09/14/2026 at 18:21, 20 hours 23 minutes ago Reporting on share buyback transactions carried out between September 7 and September 10, 2026
Published on 09/14/2026 at 17:35, 21 hours 9 minutes ago Disclosure of transactions in own shares from September 7 to September 11, 2026
Published on 09/14/2026 at 16:15, 22 hours 29 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of August 31, 2026